The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2019

Filed:

May. 06, 2015
Applicant:

Ohio University, Athens, OH (US);

Inventors:

Kelly D. McCall, Athens, OH (US);

Frank L. Schwartz, Vienna, WV (US);

Douglas J. Goetz, Athens, OH (US);

Assignee:

Ohio University, Athens, OH (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); C07D 417/14 (2006.01); A61K 31/4166 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/155 (2006.01); A61K 45/06 (2006.01); C07D 233/84 (2006.01); C07D 277/16 (2006.01); C07D 277/36 (2006.01); C07D 277/84 (2006.01); C07D 405/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); C07D 417/06 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/155 (2013.01); A61K 31/4166 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07D 233/84 (2013.01); C07D 277/16 (2013.01); C07D 277/36 (2013.01); C07D 277/84 (2013.01); C07D 405/04 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 417/06 (2013.01); Y02A 50/411 (2018.01);
Abstract

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective amount of at least one compound of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof. The pharmaceutical composition includes at least one compound of the General Formula (I) or the General Formula (II) for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.


Find Patent Forward Citations

Loading…